Table 1B.
Summary of studies using matched related donors–reduced intensity regimens
| Author | n | Diagnosis | Median Age (y) | Conditioning | GVHD prophylaxis | Chimerism (presence of donor cells) | Outcome |
|---|---|---|---|---|---|---|---|
| DeLima [16] M.D. Anderson | 94 | MDS/AML | 57 | Flu/ARA-C/Ida or Flu/Melphalan | Tacro/MTX | 24/32
40/62 |
8/32 CR/PR
42/62 CR/PR |
| Dey [37], Mass General | 82 | Heme malignancies | 43 | Cytoxan Thymic XRT ATG or Medi 507 | Cyclosporine | 60/82 | 9/22 With lost graft CR/PR |
| Bay [19], France | 5 | Metastatic ovarian cancer | 38 | Busulfan Fludarabine ATG | Cyclosporine | 4/4 evaluable | 4/4 Evaluable PR |
| Childs [17], NIH | 23 | Metastatic renal cell | 48 | Cytoxan Fludarabine | Cyclosporine | 19/19 | 10/19 Regression |
CR =complete remission; GVHD =graft-vs-host disease; MDS/AML =myelodysplastic syndrome/acute myeloid leukemia; NIH =National Institutes of Health; PR =partial remission.